Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have been diagnosed with Myasthenia Gravis (MG), confirmed by a doctor's examination and blood tests showing specific antibodies (anti-AChR or anti-MuSK)
- Your MG affects more than just your eyes and falls into a moderate-to-severe category as defined by the Myasthenia Gravis Foundation of America (class IIa, IIb, IIIa, or IIIb) (confirm with trial site)
- Your blood protein (IgG) levels are high enough to be suitable for the study treatment (confirm with trial site)
- You have either never received the study treatment (rozanolixizumab) before, or your last dose was more than 3 months ago
- Your MG symptoms score at least 3 points on a standard scale, with at least 3 of those points coming from symptoms not related to the eyes
- You are up to date with all required vaccinations in your country
- You are able to understand and sign a consent form agreeing to take part
- You are willing and able to attend all appointments and follow all study requirements
- You are covered by a European social security system
Who may not be able to join:
- You have a mental health condition, dementia, or a low score on a standard memory and thinking test that might affect your ability to take part safely
- You have any other illness or health condition that the study doctor believes could affect the results or put you at extra risk
- You have or have had a cancer (except certain fully treated skin cancers or a fully treated cervical condition)
- You currently have a significant bacterial, viral, or fungal infection that is not under control
- You are currently being treated with certain other medications, including rituximab, anti-FcRn therapies, complement inhibitors, or plasma exchange (PLEX)
- You previously stopped taking rituximab without following the specific rules required before starting this study treatment (confirm with trial site)
- You have a very advanced illness that would prevent you from being properly assessed or treated during the study
- You have an active infection that is not being treated
- You are known to be allergic to the study drug or any of its ingredients, including histidine, proline, or polysorbate 80
- You are, or a close family member is, directly involved in running this study at the trial site
- You are protected by law, under guardianship, or are otherwise unable to participate in a clinical trial under French public health law
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess in real-life the impact of the ROZ on MG symptoms PRO score in generalized MG patients with anti-AChR or anti-MUSK antibodies
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.